NCT04639466View on ClinicalTrials.gov

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions
COVID-19 Infection
Interventions
DRUG

Placebo Administration

Given IM in the non-dominant upper arm

BIOLOGICAL

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

Given IM in the non-dominant upper arm

Trial Locations (3)

91010

City of Hope Comprehensive Cancer Center, Duarte

91360

Millennium Clinical Trials, Thousand Oaks

91711

EmVenio Research, Claremont

All Listed Sponsors
lead

GeoVax, Inc.

INDUSTRY